Mobilization studies in C3-deficient mice unravel the involvement of a novel crosstalk between the coagulation and complement cascades in mobilization of hematopoietic stem/progenitor cells Hematopoietic stem/progenitor cells (HSPCs) express chemokine receptor CXCR4 and very late antigen-4 (VLA-4, also known as a 4 b 1 integrin) receptor on their cell surface, and are retained in bone marrow (BM) niches by the interaction of these receptors with their respective ligands, a-chemokine stromal-derived growth factor-1 (SDF-1) and vascular adhesion molecule-1 (VCAM-1, also known as CD106), which are expressed by cells in the BM microenvironment (for example, osteoblasts and fibroblasts). HSPCs residing in BM are released from their niches and circulate under steady-state conditions at detectable levels in the peripheral blood (PB), and their number increases in response to (i) systemic or local inflammation, (ii) strenuous exercise, (iii) stress, (iv) tissue/organ injury and (v) pharmacological agents. [1] [2] [3] [4] [5] The mobilization process has been postulated to be directed by (i) a decrease in SDF-1-CXCR4 and VLA-4-VCAM-1 interactions in BM microenvironment (for example, due to the release of proteolytic enzymes or after molecular blockade by administration of small molecular CXCR4 or VLA-4 antagonists), (ii) release of neurotransmitters from the synapses of the nerves that innervate the BM microenvironment (for example, involving the dopamine and b2-adrenergic receptors), (iii) reversal of the trans-endothelial chemotactic gradient between the BM microenvironment and plasma, (iv) activation of the plasminogen system, as recently proposed, and (v) activation of the complement cascade (ComC), as we have demonstrated. [1] [2] [3] [4] [5] Lending additional support to this latter effect, it is known that the ComC becomes activated in all the mechanisms leading to mobilization of HSPCs (for example, systemic inflammation, organ injury, strenuous exercise, as well as administration of mobilizing drugs). 2 We previously reported that mice defective in the third complement protein (C3), which is a proximal component of the ComC, are easy mobilizers. 6 This has been explained by a lack of C3a formation, which normally increases retention signals for HSPCs in response to a BM SDF-1 gradient, and thus prevents uncontrolled release of these cells into PB. By contrast, mice defective in the fifth complement protein (C5), which is a distal component of the ComC, display a profound defect in mobilization of HSPCs. 7 To explain this phenomenon, we demonstrated that C5 cleavage fragments (C5a and C5b) are essential for egress of HSPCs into PB. Accordingly, C5a generated in the BM microenvironment above the BM-PB barrier is responsible during the mobilization process for augmenting the release of proteolytic enzymes from myeloid cells, which attenuates SDF-1-CXCR4 and VLA-4-VCAM-1 retention signals in BM niches. In addition, C5a generated down from the BM-PB barrier in BM sinusoids is a potent chemoattractant for granulocytes and monocytes that, as the first cells egressing from the BM, has an important role in permeabilization of the BM-PB barrier, and thus facilitate the subsequent egress of HSPCs. 7 Moreover, another C5 cleavage fragment, C5b, is involved in the formation of C5b-C9, also known as the membrane attack complex (MAC), which increases the PB level of a potent chemoattractant for HSPCs, sphingosine-1-phosphate. 8 Thus, the failure of C5-deficient mice to generate both C5a and MAC explains why they are poor mobilizers. 7, 8 Considering the fact that activation of the ComC and proper cleavage of C3 is required for the formation of C5 convertase (an enzyme that cleaves C5 into C5a and C5b), one would expect that C3-deficient mice, like C5-deficient animals, would be poor mobilizers. However, as mentioned above and already reported, 6 this is not the case. To address why C3 À / À mice, despite a defect in the generation of C5 convertase, are easy mobilizers, we considered the involvement of alternative proteolytic pathways that could cleave/activate C5 in C3 À / À mice. For example, activation of the coagulation cascade (CoaC) is a well-known side effect of granulocyte colony-stimulating factor (G-CSF) when employed in patients for stem cell mobilization. 9 Herein, based on data that C5 can be activated/cleaved by thrombin, 10 which
Accepted article preview online 20 March 2013; advance online publication, 12 April 2013 exhibits C5 convertase-'like' activity, we evaluated the effect of thrombin inhibition during G-CSF-induced mobilization in C3 À / À and wild-type (WT) mice by employing a specific, direct thrombin inhibitor, refludan.
In our experiments, 2-month-old C3-deficient mice (C3 À / À ) were mobilized for 6 days by G-CSF (250 mg/kg subcutaneously) in the presence or absence of refludan (lepirudin), a specific thrombin inhibitor, which was administered daily for 6 days (5 mg/kg intraperotoneally). Following mobilization, mice were killed and blood was drawn from the inferior vena cava to measure the total number of white blood cells (Figure 1a) , the number of circulating clonogenic colony forming unit-granulocyte/macrophage (Figure 1b) , and the number of Sca-1 þ c-kit þ lineage -cells (Figure 1c ). In parallel, we measured the activation of C5 by measuring the level of C5a by enzyme-linked immunosorbent assay in the PB of C3 À / À mice that were non-mobilized (control), mobilized with G-CSF and mobilized with G-CSF in the presence of refludan. We observed that G-CSF-induced mobilization of HSPCs was significantly reduced in C3 À / À mice, if the mice were treated during the mobilization with refludan ( Figure 1) . Moreover, while as expected, we observed activation of C5 and release of C5a in C3 À / À mice mobilized with G-CSF, this activation was significantly inhibited in the presence of refludan. This result confirms that C5 can be activated/cleaved in a thrombin-dependent manner 10 in the absence of C3 and ComC-generated C5 classical convertaseand thus thrombin may substitute as C5 'like' convertase for the C3-dependent C5 classical convertase.
On the basis of this finding, we propose the following novel scenario for crosstalk between CoaC and ComC in the mobilization of HSPCs (Figure 2a) . As reported, G-CSF administration activates 
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mice. This substitution enables normal mobilization of HSPCs in C3
À / À mice, despite a defect in activation of the ComC.
both ComC and CoaC, which leads in normal WT animals to the generation of C5a as the result of activation of the ComC downstream from the activated/cleaved C3 and release of C5 convertase. [6] [7] [8] However, as C3 À / À mice cannot generate a 'classical' C5 convertase, they activate/cleave C5 by activation of the CoaC and generation of thrombin, which exhibits C5-'convertase-like' activity against C5 (Figure 2b) . The positive impact of thrombin on the mobilization of HSPCs was subsequently confirmed in G-CSF-mobilized WT mice (data not shown). Specifically, WT mice displayed an B20% decrease in mobilization efficiency of HSPCs in the presence of refludan, which supports the notion that thrombin is also involved in the mobilization process in normal WT animals.
The postulated crosstalk between the CoaC and ComC involves, in addition to thrombin as reported, 10 several other components of the CoaC, such as factors XI, IX, X, and even plasmin. 10 The proteolytic compensation by other components of the CoaC explains why inhibition of thrombin by refludan did not completely abolish the mobilization process in C3
À / À mice (Figure 1 ). On the other hand, as reported by others and confirmed by us, one must also consider that C5 can also be cleaved by several other proteolytic enzymes unrelated to the CoaC and ComC, such as cathepsin, matrix metalloproteinase-2 (MMP-2) and MMP-9.
10
In conclusion, the data presented in this work demonstrate, for the first time, the existence of crosstalk between two evolutionarily ancient proteolytic cascades, the ComC and CoaC, in the mobilization of HSPCs. This has important implications, because it is known that both cascades are activated in parallel in all situations, in which HSPCs are mobilized from BM into PB (for example, infections, tissue/organ damage and strenuous exercise). Moreover, both axes show a circadian rhythm of activation. 11, 12 Because of a drop in blood pH during deep sleep at night, both cascades are activated in the early morning hours 11, 12 at a time when the peak in circulating HSPCs is observed. 4 This important fact has to be taken into consideration when studying the circadian circulation of HSPCs. It is likely that, in addition to circadian changes in the tonus of the vegetative nervous system, circadian activation of the ComC and CoaC is also involved in circadian release of HSPCs from BM into PB. 4, 11, 12 This conclusion, however, needs the support of further experimental evidence.
Why do we see JAK2 exon 12 mutations in myeloproliferative neoplasms? The absence of Janus kinase 2 (JAK2) amino-acid substitution V617F in a minority of patients with myeloproliferative neoplasms (MPNs) prompted a search for additional JAK2 mutations, leading to a discovery of a mutation cluster in the 3 0 part of JAK2 exon 12.
1 These alterations comprise 440 different small deletions/duplications and substitutions of one or more amino acids between phenylalanines F533 and F547, which are located in a linker between the pseudokinase and the SH2 domains.
1,2 However, the reason for such a conspicuous clustering of MPN-associated mutations has been poorly understood.
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